Bullish on Dr Reddy's, Lupin among pharma names; Biocon still not a 'buy': Pankaj Pandey

In a chat with ET Now, Pankaj Pandey, head of research, ICICIdirect.com, talks about the Sebi’s nod to the IPO of Biocon’s arm Syngene.

ET Now: Syngene now has got the nod for an IPO. What kind of a rub off could we see for Biocon?

Pankaj Pandey: Within the pharma space, we have been more positive on the tier I names. We would want to believe that players like ​Dr Reddy’s Labs and Lupin, which did not had a very great quarter (Q4), to perform well given the ANDA filing by these drug makers that could get faster approvals.

As a result of that, the US market for them would continue to drive their topline growth. That we are positive on these two stocks. Biocon is still not recommended by us within the pharma space.